A Phase 4 interventional study of L-arginine and Sildenafil in Thalassemia, sponsored by Sherief Abd-Elsalam. Status unknown at 1 site in Egypt. Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2018-08-27.
Sponsored by Sherief Abd-Elsalam · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Thalassemia with a site in Egypt — 2 open to participants now, 2 under way, 1 of them phase 3. Thalassemia · Egypt.
Among the 17 studies in Thalassemia with a site in Egypt, this one is the 10th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2016, is one of 2 in phase 4, and was the 9th registered.
250 studies on the registry are indexed under Thalassemia; 43 are open to participants now.
Browse Thalassemia studies →2 of the 17 studies in Thalassemia with a site in Egypt are open now. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in Egypt, United States, Canada and 14 more countries
Ages 2+
Sohag University · Sites in Egypt
Ages 4–18
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 28 Thalassemia studies recruiting now, 7 (25%) set no upper age limit and 18 (64%) stop at 75 or younger; 22 take children under 18; none take healthy volunteers.
This study: 6 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 33 across 170 interventional studies indexed under Thalassemia.
Median enrollment 120 across the 11 interventional studies, 83 across the 6 observational. Of the 12 that completed or were terminated, 3 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 17 have an industry lead sponsor. The 10 most frequent:
Sherief Abd-Elsalam is the lead sponsor of 50 studies on the registry; 23 are open to participants now.
Sherief Abd-Elsalam has 1 study filed under Thalassemia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Thalassemia with a site in Egypt, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study compares L-arginine Versus Sildenafil as treatment for pulmonary hypertension in Children with Beta Thalassemia
This study focuses on different lines of treatment for pulmonary hypertension in children with thalassemia as this study discusses the Effect of L-arginine Versus Sildenafil in Children with Beta Thalassemia Associated with Pulmonary Hypertension
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
l-arginine for pulmonary hypertension in patients with thalassemia.
Drug: L-arginine
Sildenafil for pulmonary hypertension in patients with thalassemia.
Drug: Sildenafil
No pulmonary hypertension
l-arginine for thalassemia with pulmonary hypertension
Sildenafil for thalassemia with pulmonary hypertension
Also known as: Viagra
Number of patients with improvement of pulmonary hypertension
patients with improvement of pulmonary hypertension
Time frame: 6 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jul 2016 (actual). Primary completion is estimated for Dec 2023, 89 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Arginine · Sildenafil
Sherief Abd-Elsalam